(Q51953747)

18 April 2018

title

Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. (English)

1 reference

18 April 2018

author name string

Wedad M Hanna

series ordinal

1

1 reference

18 April 2018

Kevin Kwok

series ordinal

2

1 reference

18 April 2018

publication date

1 April 2006

1 reference

18 April 2018

published in

Modern Pathology

1 reference

18 April 2018

volume

19

1 reference

18 April 2018

issue

4

1 reference

18 April 2018

page(s)

481-487

1 reference

18 April 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.3800555

exact match

0 references

cites work

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Targeted therapy in breast cancer: the HER-2/neu gene and protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Emerging technologies for HER2 testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Current perspectives on HER2 testing: a review of national testing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

21 January 2018

Testing for HER2 status

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

The predictive value of HER2 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800555

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/MODPATHOL.3800555

1 reference

18 April 2018

PubMed ID

16444193

1 reference

18 April 2018